ClinicalTrials.gg
CompletedNCT04919551Updated Nov 1, 2021

A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects

A Phase 1 interventional study of vicagrel in Acute Coronary Syndrome, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Acute Coronary Syndrome with a site in China — 56 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Enrollment
111th of 115
24 · median 499
Started
2021
with 11 others
Phase 1
5 of 185
1 open now
Registered
111th of 185
by date
Lead sponsor
4 of 185
Jiangsu vcare pharmaceutical technology co., LTD

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 111th largest by enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2021, is one of 5 in phase 1, and was the 111th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

56 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

This clinical study will adopt a randomized, open-label, single-dose, 3-cycle, 3-way crossover design to explore the PK and PD profiles of a single oral dose of vicagrel capsules under fasted and fed conditions in health subjects.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of before the trial, and full understanding of the experimental content, process and possible ARs;
  • Able to complete the study according to the protocol;
  • Subjects (and their partners) are willing to take effective measures from screening to 6 month after the last dose of the IMPs. See Appendix 5 for specific contraceptive measures;
  • Male and female subjects aged 18 to 45 years (inclusive);
  • Male weight ≥50 kg, female weight ≥ 45 kg. (BMI) = body weight (kg) / height2 (m2). BMI ranging from 18 to 28 kg/m2 (including critical values);
  • Physical examination and vital signs are normal or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  • More than 5 cigarettes per day on average 3 months before the trial;
  • Allergic constitution (allergic to multiple drugs and foods), or known to be possibly allergic to drugs of the same class of the IMP or highly sensitive to clopidogrel;
  • History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or use of hard drug within the past five years;
  • Blood donation or massive blood loss (>450 mL) within 3 months before screening;
  • Presence of dysphagia or history of any gastrointestinal and hepatic, renal disease (whether cured or not) or history of surgery that affects absorption or excretion of the IMP within 6 months prior to screening;
  • With any disease that increases the risk of bleeding, such as acute gastritis, stomach and duodenal ulcers, or history of abnormal bleeding (e.g. bleeding time prolonged after tooth extraction);
  • The subject or his or her immediate family member has a family history of coagulation or haemorrhagic disorders (such as haemophilia)/symptoms (such as hematemesis, melena, severe or recurrent epistaxis, coughing blood (hemoptysis), obvious hematuria or intracranial hemorrhage), or suspected vascular malformation, such as aneurysm or early-onset stroke;
  • Took potent inhibitors and/or inducers of CYP enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days prior to the first dose. Potent inhibitors of CYP enzymes include ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc.. Potent inducers of CYP enzymes include rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc.. See Appendix 6 for details;
  • Took any prescription, non-prescription, any vitamin or herbal drugs within 14 days before the first dose;
  • Had foods that affect metabolism within 2 weeks prior to the first dose, such as grapefruit or grapefruit-containing beverages, or had intense physical exercise (e.g. strength training, aerobic training, and playing football) within 7 days prior to the first dose, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
  • Recently there have been major changes in diet or exercise habits;
  • Participated in a another clinical study within 3 months prior to screening (a subject may be enrolled if he/she withdraws from the study prior to treatment, i.e., the subject is not randomized or doesn't receive treatment);
  • Failure to tolerate high-fat meals (two boiled eggs, one slice of toast with butter and bacon, a box of French fries, a glass of whole milk);
  • 12-lead abnormalities have clinical significance;
  • Female subjects who are in lactation or positive for serum pregnancy test in the screening period or during the trial;
  • Clinical laboratory abnormalities have clinical significance or other diseases before screening (including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, and lung, immune, mental or cardiovascular and cerebrovascular diseases);
  • Positive for viral hepatitis (including and C), antibody and treponema pallidum antibody during screening;
  • Any acute diseases or concomitant medicines from screening period to before taking the IMPs;
  • Took chocolate, any food or drink with caffeine or xanthine within 24 hours before the first dose;
  • Took any alcoholic product or alcohol breath test is positive within 24 hours before the first dose;
  • Urine drug screening positive;
  • The investigator believes that there are other factors that are not suitable for participating in the trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    KGD

    Oral administration after fasting/high-fat meal/low-fat meal

    Drug: vicagrel

  • Experimental
    GDK

    Oral administration after high-fat meal/low-fat meal/fasting

    Drug: vicagrel

  • Experimental
    DKG

    Oral administration after low-fat meal/fasting/high-fat meal

    Drug: vicagrel

Interventions

  • Oral administration after fasting/high-fat meal/low-fat meal

06

What researchers measure

Primary outcomes

  1. AUC

    Area Under the Curve From Time Zero to Last Quantifiable Concentration

    Time frame: 48 hours

  2. Cmax

    Peak concentration

    Time frame: 48 hours

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Oct 2021, 1 month.

Of 16 phase 1 interventional studies under Acute Coronary Syndrome, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 14. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jun 9, 2021
StartActual
Aug 24, 2021
Primary completionActual
Oct 20, 2021
CompletionActual
Oct 20, 2021
Last update
Nov 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04919551
Responsible party
Sponsor
First posted
Jun 9, 2021
Start date
Aug 24, 2021
Primary completion
Oct 20, 2021
Completion
Oct 20, 2021
Last update
Nov 1, 2021

Study contacts

Yanhua Ding
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumecigrel

Start the discussion